| Ytd | 12.01% | |
| 1y | 2.00% |
| Open | 6.25 | Prev Close | 6.21 | Low | 6.25 | High | 7.97 | Mkt Cap | 7.27M |
| Vol | 66.75K | Avg Vol | 54.63K | EPS | -3.71 | P/E | N/A | Forward P/E | -5.97 |
| Beta | 0.65 | Short Ratio | 0.50 | Inst. Own | 1.99% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | 6.36 | 200-d Avg | 8.93 | 1yr Est | 20.00 |
TransCode Therapeutics announced successful completion of Phase 1a clinical trial for TTX-MC138, sho
TransCode Therapeutics (NASDAQ:RNAZ) reported quarterly losses of $(21.28) per share. This is a 69.6
TransCode Therapeutics, Inc.15,955,543 SharesCommon StockThis prospectus relates to the possible res
TransCode Therapeutics, Inc. (NASDAQ:RNAZ, the ", Company", )), a clinical stage company pio
TransCode adds a unique adenovirus technology platform to its early-stage pipeline that has the pote
As part of the PRE-I-SPY platform, the TTX-MC138 Phase 2a dose-expansion portion of the trial will e
Shares of TransCode Therapeutics, Inc. (NASDAQ: RNAZ) fell sharply during Friday’s session. TransCo
Shares of Airspan Networks Holdings Inc. (NASDAQ: MIMO) shares rose sharply during Wednesday’s sessi
Gainers Apollomics, Inc. (NASDAQ: APLM) shares surged 88.4% to $1.07 stoma multiforme with PTPRZ
Gainers NKGen Biotech, Inc. (NASDAQ: NKGN) shares surged 60.9% to $6.08 in pre-market trading after
Gainers